Beijing Lüzhu Biotechnology Co., Ltd.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: CNE100005YD8

HKD

23.02

0.00 (0.00%)

Dec 12

HKG

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Wuxi Biologics (Cayman), Inc.

3SBio, Inc.

Alphamab Oncology

CSPC Pharmaceutical Group Ltd.

Sirnaomics Ltd.

Laekna, Inc.

Ascentage Pharma Group International Co., Ltd.

AIM Vaccine Co., Ltd.

Zai Lab Ltd.

Beijing Lüzhu Biotechnology Co., Ltd.

Genscript Biotech Corp.

Why is Beijing Lüzhu Biotechnology Co., Ltd. ?

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

Poor long term growth as Net Sales has grown by an annual rate of % and Operating profit at 0.00% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -250.53

Flat results in Dec 24

NO KEY NEGATIVE TRIGGERS

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -7.36%, its profits have fallen by -19%

Below par performance in long term as well as near term

Along with generating -7.36% returns in the last 1 year, the stock has also underperformed Hang Seng Hong Kong in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Beijing Lüzhu Biotechnology Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Beijing Lüzhu Biotechnology Co., Ltd.

-7.36%

0.35

46.21%

Hang Seng Hong Kong

27.36%

1.06

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

-250.53

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.47

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.16

EV to EBIT

-29.10

EV to EBITDA

-35.26

EV to Capital Employed

8.55

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-29.39%

ROE (Latest)

-18.62%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bullish

Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Beijing Lüzhu Biotechnology Co., Ltd.

Pre-Tax Profit

At HKD -69.52 MM has Grown at 62.4%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit

At HKD -69.52 MM has Grown at 62.4%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)